AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2020

January 21, 2020 GMT

ROCKVILLE, Md.--(BUSINESS WIRE)--Jan 21, 2020--

BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ):

 

 

Six Months Ended
November 30,

 

Three Months Ended
November 30,

 

 

2019

 

2018

 

2019

 

2018

 

Revenue 

 

$

21,290,838

 

$

18,014,347

 

$

11,222,962

 

$

8,361,478

 

Income Before Income Tax 

 

$

3,132,524

 

$

1,698,986

 

$

1,258,041

 

$

811,813

 

Net Income 

 

$

2,216,324

 

$

1,201,986

 

$

891,841

 

$

574,313

 

Basic Earnings per Share of Common Stock 

 

$

2.48

 

$

1.35

 

$

1.00

 

$

.64

 

Diluted Earnings per Share of Common Stock 

 

$

2.48

 

$

1.35

 

$

1.00

 

$

.64

 

Weighted Average Number of Shares Outstanding For Basic Earnings Per Share

 

 893,416

 

 

 893,416

 

 

893,416

 

 

893,416

 

Weighted Average Number of Shares Outstanding For Diluted Earnings Per Share

 

 

893,838

 

 

893,579

 

 

893,838

 

 

893,579

For more detail related to the fiscal year 2020 unaudited second quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200121005789/en/

Mark G. Lewis, Ph.D., CEO (240-404-7654)

KEYWORD: UNITED STATES NORTH AMERICA MARYLAND

INDUSTRY KEYWORD: BIOTECHNOLOGY SCIENCE HEALTH RESEARCH

SOURCE: BIOQUAL, Inc.

Copyright Business Wire 2020.

PUB: 01/21/2020 11:05 AM/DISC: 01/21/2020 11:05 AM

http://www.businesswire.com/news/home/20200121005789/en